Back to Agenda
Session 5: Lessons from Post-Market Surveillance on How to Bridge Safety, Quality, and Device Risk
Session Chair(s)
Ranjeeta Sinvhal, MD
Executive Medical Director, Medical Safety, AbbVie, United States
Combination drug-device products sit at the intersection of safety, quality, and device risk management, and post-market surveillance is where those disciplines either work together or work in silos. This session examines how safety and quality functions partner in practice: applying ICH Q9 principles to prospective Quality Risk Management, using adverse event data to inform continued process verification and signal detection, and supporting ad hoc or for-cause Health Risk Assessments and product recalls. Speakers will also address drug-device combination product surveillance specifically, including how post-market safety data shapes target product profiles and device development, how medication error data collection and term selection inform device design and user instructions, and how organizations decide between device risk management and Health Risk Assessment escalation pathways. The session will include case examples throughout and may reference the MedDRA Points to Consider Companion Document Section 5 on manufacturing and quality system issues, with perspectives from MedDRA MSSO, industry, and FDA.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Use post-market safety data, including medication errors and adverse event trends, to guide device design.
- Decide when a safety issue needs device risk management versus a formal Health Risk Assessment.
- Apply ICH Q9 principles to signal detection and continued process verification.
Have an account?